LLY compared with ZVRA: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

ZVRAZevra Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

ZVRAZevra Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only LLY 29

MCKMcKessoncustomer

CAHCardinal Healthcustomer

VEEVVeeva Systemssupplier

UTHRUnited Therapeuticscustomer

25 more · LLY chain ›

Shared 0

No shared counterparties.

Only ZVRA 6

—Aquestive Therapeuticsunlistedsupplier

—Orphazyme A/Sunlistedsupplier

—Reliefunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—

Xoma

unlistedsupplier

2 more · ZVRA chain ›

LLYELI Lilly & Co

1,360.90▼−0.28%· post 1,358.90

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

ZVRAZevra Therapeutics, Inc.

11.60▲+10.15%· post 11.61

ClosedNov 6 '26

Mkt cap$689.7MRevenue$38MQ3 FY26Revenue$106MFY25

Compare

ClosedNov 6 '26

LLYELI Lilly & Co

ZVRAZevra Therapeutics, Inc.

1,360.90▼−0.28%post 1,358.90

Price

11.60▲+10.15%post 11.61

$1.2T

Mkt cap

$689.7M

Q3 FY26$24.4B

Revenue

$38MQ3 FY26

FY25$65.2B

Revenue

$106MFY25

LLY1,360.90▼−0.28%vsZVRA11.60▲+10.15%ClosedNov 6 '26